Medigen Biotechnology Corporation AI Stock Analysis
Medigen Biotechnology Corporation (3176) AI Stock Analysis
Medigen Biotechnology Corporation
(TPEx:3176)
Medigen scores low overall because, despite a genuinely improving financial trajectory, the business is still loss-making at every operating level with negative free cash flow and a steadily eroding equity base that now funds only about a quarter of total assets. Credit is due for the sharp debt reduction, restored ~54% gross margin and a swing to positive operating cash flow, but revenue has proven highly volatile since the pandemic-era peak. Technicals reinforce caution, with the price below all key moving averages and a negative MACD, though oversold RSI and Stochastic readings suggest selling may be extended. Valuation offers little support given the negative P/E and absence of a dividend. The stock remains a speculative turnaround candidate pending evidence of sustained operating profitability.
Medigen Biotechnology Corporation (3176) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 628.92K
- Price to Earnings (P/E)
- -16.6
- Beta (1Y)
- 0.40
- Revenue Growth
- 1.11%
- EPS Growth
- -94.39%
- Country
- TW
- Employees
- 67
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Medigen Biotechnology Corporation Business Overview & Revenue Model
Company Description
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural kil...
Medigen Biotechnology Corporation Financial Statement Overview
Summary
Medigen is a turnaround in progress. Revenue has rebuilt to roughly NT$1.58 billion with gross margins stabilizing around 53-55%, a dramatic recovery from 6.9% in 2022, and net losses have narrowed four straight years to NT$109 million. Leverage has been cut sharply, with debt down from NT$2.91 billion to NT$953 million and debt-to-equity falling from 1.83x to 0.61x, while operating cash flow turned positive at NT$49 million. However, the company remains unprofitable at both operating (-9.9% margin) and net level, EBITDA fell to NT$18.6 million, free cash flow is still negative at about -NT$22 million, ROE is -7.0%, and shareholders' equity has eroded every year to NT$1.55 billion, funding only about a quarter of the asset base. Revenue volatility since the pandemic peak adds further risk.
Income Statement
42NeutralBalance Sheet
48NeutralCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.32B | 1.58B | 1.37B | 1.16B | 1.06B | 3.92B |
| Gross Profit | 624.60M | 857.73M | 753.76M | 617.33M | 73.07M | 2.53B |
| EBITDA | -42.55M | 18.64M | 98.91M | -1.04B | -1.64B | 1.35B |
| Net Income | -252.36M | -108.80M | -204.69M | -561.30M | -675.87M | -52.61M |
Balance Sheet | ||||||
| Total Assets | 6.90B | 6.18B | 6.71B | 8.53B | 9.98B | 8.20B |
| Cash, Cash Equivalents and Short-Term Investments | 2.72B | 2.50B | 2.59B | 4.59B | 5.07B | 3.00B |
| Total Debt | 1.72B | 952.79M | 1.07B | 2.91B | 2.81B | 1.04B |
| Total Liabilities | 2.19B | 1.46B | 1.67B | 3.53B | 3.51B | 1.77B |
| Stockholders Equity | 1.48B | 1.55B | 1.58B | 1.59B | 2.19B | 2.39B |
Cash Flow | ||||||
| Free Cash Flow | -464.55M | -22.41M | -20.76M | -545.42M | -1.28B | 372.90M |
| Operating Cash Flow | -44.62M | 49.03M | 37.92M | -503.52M | -1.13B | 517.45M |
| Investing Cash Flow | -468.51M | 44.34M | 903.30M | 497.66M | -692.67M | -369.75M |
| Financing Cash Flow | 579.70M | -157.26M | -1.77B | 193.15M | 1.72B | -209.29M |
Medigen Biotechnology Corporation Peers Comparison
Overall Rating
- TW:317642Neutral
TW:679440Underperform
TW:472635Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:3176 | 42Neutral | TWD 4.62B | -16.65 | ― | ― | 1.11% | -94.39% |
| TW:6794 | 40Underperform | TWD 4.10B | -34.13 | ― | ― | -48.98% | -2.09% |
| TW:4726 | 35Underperform | TWD 4.76B | -12.16 | ― | ― | 52.81% | 38.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:3176 | Medigen Biotechnology Corporation | 30.10 | 0.20 | 0.67% | |
| TW:4726 | Mycenax Biotech Inc. | 22.40 | -11.25 | -33.43% | |
| TW:6610 | TWi Biotechnology, Inc | 17.50 | -19.34 | -52.50% | |
| TW:6634 | Sinew Pharma, Inc. | 63.20 | 22.70 | 56.05% | |
| TW:6794 | UnicoCell Biomed Co., Ltd. | 64.80 | -6.20 | -8.73% | |
| TW:7902 | Uwell Biopharma Inc. | 25.45 | -2.15 | -7.79% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026